MedTrace Logo

Outcome Study to Evaluate Klaricid XL® (Clarithromycin Modified Release) in Patients With Acute Exacerbation of Chronic Bronchitis

NCT01354938 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 220

Last updated 2013-02-06

Study results available
· View outcomes & findings →

Summary

The objective of this study was to evaluate the role of Klaricid XL (clarithromycin modified release) in the treatment of acute exacerbation of chronic bronchitis (AECB) and its impact on improving the quality of life.

Conditions

  • Bronchitis

Interventions

DRUG

Clarithromycin modified release 500 mg

Clarithromycin modified release 500 mg was prescribed. The dosage given was either 1 tablet or 2 tablets once a day, depending on the severity of the treatment.

Sponsors & Collaborators

Principal Investigators

  • Raeef Ahmed, MD · Abbott

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01354938 on ClinicalTrials.gov